MARKETSnap
  • Market Snapshots
    • Gainers & Losers
    • Most Active & More
    • 52-Week High/Low
    • Dividends
    • P/E Ratios
      • Large Caps
      • Absolute
      • Total Market PE
    • Stocks Performance
      • Large Caps
      • Absolute
    • Industries Performance
      • Industry
      • Sector
  • Analyze Stock
    • Analyze a stockAnalyze BSX →
    • FindStock Picks / Stock Screener
    • Value · BSXIntrinsic Value Calculator
    • Invest · BSXInvestment Case
    • Hold · BSX5-Year Outlook
  • Learn
  • Calendar
  • Investment Compounding
    Calculator
  • Investing Philosophy
  • More
    • Charts
    • Commodities
    • Currencies
    • Economic Indicators
      • Inflation
      • Consumer Sentiment
      • Recession Probability
      • Treasury Rates
      • GDP
BSX stock logo

BSX

Boston Scientific Corporation

$44.34
0.14
 (0.32%)
Exchange:  NYSE
Market Cap:  64.269B
Shares Outstanding:  1.48B
Delayed data
Overview
Earnings
Financials
Valuation
Chart

About The Company

Sector:  HealthcareView sector performance
Industry:  Medical – DevicesView industry performance
   
CEO:  Michael F. Mahoney
Full Time Employees:  59000
Address: 
300 Boston Scientific Way
Marlborough
MA
01752-1234
US
Website:  https://www.bostonscientific.com
Boston Scientific Corporation (BSX) operates as a global leader in medical technology, specializing in the design, manufacturing, and commercialization of innovative medical devices tailored for a diverse array of interventional medical specialties across the globe. Its business is strategically organized into three principal segments: MedSurg, Rhythm and Neuro, and Cardiovascular. Within these divisions, the company provides a comprehensive portfolio of solutions addressing various gastrointestinal and pulmonary ailments, as well as urological and pelvic health concerns. This extends to advanced implantable devices for managing cardiac rhythm disorders, such as cardioverter-defibrillators, cardiac resynchronization therapy devices, and pacemakers, complemented by remote patient management systems. Furthermore, Boston Scientific offers sophisticated technologies for diagnosing and treating complex heart rate and rhythm irregularities. These encompass 3-D cardiac mapping and navigation tools, along with a suite of specialized catheters (including ablation, diagnostic, mapping, and intracardiac ultrasound types), delivery sheaths, and related accessories. Its offerings also extend to neurological conditions, providing spinal cord stimulator systems for chronic pain management, indirect decompression systems, and deep brain stimulation systems. In the realm of interventional cardiology, the company’s innovations include drug-eluting coronary stent systems designed for treating coronary artery disease, products for percutaneous coronary interventions to combat atherosclerosis, and intravascular imaging catheters (such as ultrasound and fractional flow reserve devices) for assessing coronary arteries, heart chambers, and peripheral vessels. It also develops structural heart therapies. Beyond this, Boston Scientific supplies an array of stents, balloon catheters, wires, and atherectomy systems for the treatment of arterial diseases. For venous conditions, it provides thrombectomy and acoustic pulse thrombolysis systems, alongside wires and stents. Critically, the company also contributes to cancer treatment through peripheral embolization devices, radioactive microspheres, various ablation systems (including cryotherapy), and micro and drainage catheters. The organization was established in 1979 and maintains its corporate headquarters in Marlborough, Massachusetts.

Click to read more…

Revenue Segmentation

Revenue by type

Revenue by region

Log in to continue

Log in to see the complete revenue and geographic breakdown.

Log in — it's free

BSX full analysis

29/10/2026

Welcome back to MarketSnap. Let me start with a contradiction that's been bothering me. Boston Scientific is down almost 60% over the past year. Its medical-devices industry is roughly flat over the same stretch, and healthcare as a sector is actually up a touch. So this isn't a sector falling apart — it's one company being repriced. On Wednesday's session, the stock fell another 6% after the company cut its fourth-quarter sales and full-year earnings guidance, citing the cyberattack. It…

Listen to full analysis (audio file)

Open in MarketSnap Listen

Log in to continue

Log in to see the full analysis preview and audio links.

Log in — it's free

Industry Peers

TICKERCOMPANYMKT CAPP/EFWD P/EROIC
BSBSX logoBSXBoston Scientific Corporation64.3B18.714.010.5%
EWEW logoEWEdwards Lifesciences Corporation61.6B60.535.59.3%
GEGEHC logoGEHCGE HealthCare Technologies Inc.37.5B17.516.57.8%
DXDXCM logoDXCMDexCom, Inc.31.1B32.230.924.0%
PHPHG logoPHGKoninklijke Philips N.V.29.5B27.216.66.6%
ZBZBH logoZBHZimmer Biomet Holdings, Inc.19.5B26.012.15.3%

EPS

Historical EPS and analyst estimates in one chart. Log in for the full interactive view and links to detailed estimates.

Log in to continue

Log in for the full EPS chart and links to analyst estimates.

Log in — it's free
View full analyst estimates

Earnings Call

Full text

Earnings transcript

Read the complete earnings call transcript.

AI summary

Key takeaways

Short, structured highlights from the call so you can focus on what matters.

2026/10/28 — 3 quarter 2026

Log in to continue

Log in to read the full transcript and AI-generated earnings summaries.

Log in — it's free
Income Statement
Balance Sheet
Cash Flow Statement
Analyst Estimates

Income Statement

Year202320242025
Revenue14,240,00016,747,00020,074,000
Gross Profit8,831,00010,267,00013,853,000
EBITDA3,453,0003,938,0005,102,000
Operating Income2,181,0002,635,0003,971,000
Net Income1,593,0001,854,0002,886,000

Log in to continue

Log in to see the income statement and 10 historical years.

Log in — it's free

(* All numbers are in thousands)

Balance Sheet

Year202320242025
Total Assets35,136,00039,395,00043,673,000
Total Liabilities15,606,00017,392,00019,201,000
Total Stockholders Equity19,282,00021,770,00024,233,000
Total Debt9,492,00011,147,00011,436,000
Cash and Cash Equivalents865,000414,0001,965,000

Log in to continue

Log in to see the balance sheet and 10 historical years.

Log in — it's free

(* All numbers are in thousands)

Cash Flow Statement

Year202320242025
Operating Cash Flow2,503,0003,435,0004,534,000
Capital Expenditure-800,000-790,000-876,000
Free Cash Flow1,703,0002,645,0003,658,000
Net Income1,592,0001,846,0002,892,000
Net Change in Cash-82,000-449,0001,541,000

Log in to continue

Log in to see the cash flow statement and 10 historical years.

Log in — it's free

(* All numbers are in thousands)

Analyst Estimates

Fiscal Year2030Research AccessResearch AccessResearch AccessResearch Access
Estimated Revenue (Low)25,205,326.948Research AccessResearch AccessResearch AccessResearch Access
Estimated Revenue (High)26,646,597.549Research AccessResearch AccessResearch AccessResearch Access
Estimated Revenue (Avg)25,569,333.333Research AccessResearch AccessResearch AccessResearch Access
Estimated Ebitda (Low)8,798,196.213Research AccessResearch AccessResearch AccessResearch Access
Estimated Ebitda (High)9,340,648.580Research AccessResearch AccessResearch AccessResearch Access
Estimated Ebitda (Avg)8,935,203.761Research AccessResearch AccessResearch AccessResearch Access
Estimated Net Income (Low)5,879,093.993Research AccessResearch AccessResearch AccessResearch Access
Estimated Net Income (High)6,318,028.644Research AccessResearch AccessResearch AccessResearch Access
Estimated Net Income (Avg)5,989,956.004Research AccessResearch AccessResearch AccessResearch Access
Estimated SGA Expense (Low)9,013,160.552Research AccessResearch AccessResearch AccessResearch Access
Estimated SGA Expense (High)9,528,543.802Research AccessResearch AccessResearch AccessResearch Access
Estimated SGA Expense (Avg)9,143,325.417Research AccessResearch AccessResearch AccessResearch Access
Estimated EPS (Avg)4.010Research AccessResearch AccessResearch AccessResearch Access
Estimated EPS (High)4.230Research AccessResearch AccessResearch AccessResearch Access
Estimated EPS (Low)3.930Research AccessResearch AccessResearch AccessResearch Access
Number of Analysts (Estimated Revenue)12Research AccessResearch AccessResearch AccessResearch Access
Number of Analysts (Estimated EPS)3Research AccessResearch AccessResearch AccessResearch Access

Log in to continue

Log in with Research Access to see up to 5 years of analyst estimates.

Create a free account

(* All numbers are in thousands)

Current Key Metrics

?Revenue
 (TTM)
: 
16.747B  ?P/S
 (TTM)
: 
3.05
?Net Income
 (TTM)
: 
1.854B  ?P/E
 (TTM)
: 
18.71
?Enterprise Value
 (TTM)
: 
75.613B  ?EV/FCF
 (TTM)
: 
22.7
?Dividend Yield
 (TTM)
: 
0%  ?Payout Ratio
 (TTM)
: 
0%
?ROE
 (TTM)
: 
13.87%  ?ROIC
 (TTM)
: 
10.46%
?Net Debt
 (TTM)
: 
10.703B  ?Debt/Equity
 (TTM)
: 
0.47
?P/B
 (TTM)
: 
2.51  ?Current Ratio
 (TTM)
: 
1.36

Log in to continue

Log in to see all key valuation metrics and ratios for this symbol.

Log in — it's free

Forward P/E Ratios

?

Forward P/E (Avg EPS estimate) — log in with Research Access for high/low estimates and the interactive table.

Forward P/E 1YResearch AccessResearch AccessResearch AccessResearch Access
14.03Research AccessResearch AccessResearch AccessResearch Access

Log in to continue

Log in with Research Access for forward P/E high/low estimates and the full multi-year table.

Create a free account

SWOT Analysis

Strengths (preview)

  • Strong long-term revenue trajectory and profitability expansion: FY revenue grew from $9.91B (2020) to $20.07B (2025), with net income rising from a loss of $82M to $2.89B over the same period. TTM gross margin of 71.2%, net margin of 17.5%, ROE of 14.9%, and ROIC of 10.6% indicate efficient scale economics.
  • Robust free cash flow generation: FCF grew from $596M (2016) to $3.66B (2025), with a TTM FCF yield of 5.48%, supporting internal investment and balance-sheet flexibility.
  • Diversified portfolio and geographic mix: Three segments (MedSurg, Rhythm and Neuro, Cardiovascular) with Cardiovascular contributing $13.27B of FY2025 revenue; U.S. revenue of $12.86B vs. non-U.S. $7.21B provides balanced exposure.

Log in with Research Access for Weaknesses, Opportunities, Threats, and the complete SWOT.

Log in to continue

Log in with Research Access for the complete SWOT analysis.

Create a free account

At what price to buy it? -
Intrinsic Value Calculator

Based on current fundamentals and analyst forecasts, MarketSnap estimates BSX intrinsic value between $53.58 – $62.93 per share. This depends on revenue growth, margins, and discount rate.

This is an automatic estimate. The most reliable way to know fair value for your own assumptions is to run the calculator below.


Calculate BSX Intrinsic Value

Common questions about BSX valuation

Is Boston Scientific Corporation (BSX) overvalued or undervalued right now?

MarketSnap estimates intrinsic value for Boston Scientific Corporation (BSX) using its proprietary valuation methodology, which incorporates discounted cash flow (DCF) analysis together with long-term earnings and fundamentals assumptions. By comparing intrinsic value to the current market price, long-term investors can see whether the stock screens as potentially overvalued, fairly valued, or undervalued today.

Is BSX a buy, hold, or sell for long-term investors?

MarketSnap does not give one-word “buy” or “sell” calls. Instead, it shows whether BSX trades at a premium or discount to its estimated intrinsic value, how sensitive that value is to growth and margin assumptions, and how the stock fits into a diversified, long-term portfolio so investors can make their own buy, hold, or sell decision.

What is BSX’s P/E ratio?

You can see BSX’s trailing P/E (TTM) and forward P/E estimates in the Current Key Metrics and Forward P/E Ratios sections above. The P/E ratio compares the current share price to earnings per share and helps investors gauge valuation relative to earnings.

How is intrinsic value calculated for BSX?

MarketSnap uses its own valuation framework—not a generic spreadsheet DCF alone. Future cash flows and earnings are projected, discounted, and combined with MarketSnap’s methodology so intrinsic value reflects fundamentals and long-term assumptions. You can run your own inputs and see the result using the Intrinsic Value Calculator above.

Is BSX a good long-term investment?

Whether BSX fits a long-term portfolio depends on your assumptions about growth, margins, and risk. MarketSnap provides the metrics, intrinsic value calculator, and SWOT context so you can form your own view rather than rely on a single buy/sell rating.

Research tools for Boston Scientific Corporation

  • Boston Scientific Corporation intrinsic value calculatorEstimate what the business is worth
  • Boston Scientific Corporation 5-year outlookWhat has to go right, and what could go wrong
BSX

1-day price chart preview. Log in for 1W through 5Y ranges and period tabs.

Daily snapshot

0.32
MarketSnap

Trading Metrics:

Open: 44.69   Previous Close: 44.2
Day Low: 44.08   Day High: 44.69
Year Low: 39.57   Year High: 104.62
Price Avg 50: 44.06   Price Avg 200: 54.38
Volume: 9.697M   Average Volume: 19.563M

Log in to continue

Log in for multi-period charts (1W–5Y), period tabs, and the same layout as members.

Log in — it's free
See in Nexus

Relevant news

Boston Scientific Bets on WATCHMAN Growth Despite Market Slowdown
12-11-2026 13:25
Boston Scientific Bets on WATCHMAN Growth Despite Market Slowdown
Boston Scientific Targets Long-Term Growth as Key Businesses Face Pressure Through 2027
11-11-2026 10:15
Boston Scientific Targets Long-Term Growth as Key Businesses Face Pressure Through 2027
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Boston Scientific Corporation - BSX
10-11-2026 18:21
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Boston Scientific Corporation - BSX
Here is What to Know Beyond Why Boston Scientific Corporation (BSX) is a Trending Stock
05-11-2026 10:01
Here is What to Know Beyond Why Boston Scientific Corporation (BSX) is a Trending Stock
Is BSX Worth Buying Now as Low Valuation Meets Weak Earnings Growth?
03-11-2026 10:26
Is BSX Worth Buying Now as Low Valuation Meets Weak Earnings Growth?
SIMPLAAFY study of the WATCHMAN FLX™ Pro Left Atrial Appendage Closure Device meets primary endpoints
02-11-2026 14:02
SIMPLAAFY study of the WATCHMAN FLX™ Pro Left Atrial Appendage Closure Device meets primary endpoints

DISCLAIMER: The stock market data provided on this website is for informational purposes only and is not intended for trading purposes. While we strive to provide accurate and timely information, we cannot guarantee that the information is accurate at the moment it is received or that it will continue to be accurate in the future. We are not responsible for any actions taken based on the information provided on this website. Always consult with a licensed financial professional before making any investment decisions.
Terms of Service

Copyright © 2025 MarketSnap. All rights reserved.

How MarketSnap works

What’s new

Contact Us

Privacy Policy

Cookie Policy

Terms of Service

Hover Image
MARKETSnap

Market

🇺🇸 United States

Language

    • Gainers & Losers
    • Most Active & More
    • 52-Week High/Low
    • Dividends
      • Large Caps
      • Absolute
      • Total Market PE
      • Large Caps
      • Absolute
      • Industry
      • Sector
    • Analyze a stockAnalyze BSX →
    • FindStock Picks / Stock Screener
    • Value · BSXIntrinsic Value Calculator
    • Invest · BSXInvestment Case
    • Hold · BSX5-Year Outlook
  • Learn
  • Calendar
  • Investment Compounding Calculator
    • Charts
    • Commodities
    • Currencies
      • Inflation
      • Consumer Sentiment
      • Recession Probability
      • Treasury Rates
      • GDP
  • Investing Philosophy
  • Nexus
    • Recent Activity
      • Overview
      • My Valuations
      • My Investment Journal
      • Watchlists & Portfolio
    • Settings
    • Public profile ↗
  • Log in

Media

Watch Listen Read
Ask MarketSnap AI

MarketSnap AI Assistant

Uses MarketSnap data and this page

Ready

🔒 You are currently logged out

Login

It's free

MarketSnap Assistant · Tips
    MarketSnap

    Welcome to MarketSnap

    The AI-powered workspace for stock pickers.

    Continue with Google Continue with email

    Already a member? Sign in

    Find stocks·Value them·Build the case·Journal decisions·Track what changes

    Free to join. No card needed. Privacy Policy

    Create your free MarketSnap account Continue with Google
    Chat with us MarketSnap support · account, plans, settings, help
    How MarketSnap works

    The conversation above goes to the MarketSnap team with your message. We reply by e-mail.